Redeye Feed

2025-11-07 08:56:00 Medivir (Q3 Review) - New Phase II Study

2025-11-07 08:53:00 W5 Solutions (Q3 Review) - Strong year-end in sight

2025-11-07 08:52:00 Xspray Pharm (Q3 update) - Two PDUFA dates in 2026

2025-11-07 08:51:00 Absolent (Q3 Review) - Some positive signs

2025-11-07 08:50:00 GomSpace (Q3 Review) - Upward Revisions of Forecasts and Valuation

2025-11-07 08:49:00 Arise (Q3 Review) - Eventful months to come

2025-11-07 08:48:00 Optomed Q3 (Review) - Solid growth with a positive devices segment development

2025-11-07 08:47:00 Fable Media Group - Guidance Cut, but a Stronger Year Ahead

2025-11-07 08:46:00 Kontigo Care (Q3 Review) - Back to growth with profitability on the rise

2025-11-07 08:45:00 Transtema (Q3 Review) - Focus on profitability in 2026

2025-11-07 08:44:00 NextCell Pharma (Q4 2024/2025 update) - ProTrans-Young readout in Q3 2026

2025-11-07 08:43:00 G5 Entertainment (Q3 Review) - Improved prospects for a growth turnaround

2025-11-07 08:41:00 Devyser Diagnostics (Q3 Review) - Exaggerated reaction, strong Q4 ahead

2025-11-07 08:40:00 Cheffelo (Q3 Review) - Dish of the quarter, returned untouched

2025-11-07 08:39:00 Oncopeptides (Q3 Update) - Q/Q Growth Only 5%, but 2026 Looks Promising

2025-11-07 08:38:00 Bredband2 (Q3 Review) - All Eyes on Regulatory Approvals

2025-11-07 08:37:00 Neola Medical (Q3 Review) - Revised timeline

2025-11-05 16:27:00 Freemelt (Q3 Review) - Maintaining strong momentum

2025-11-05 11:15:00 Serstech (Q3 Review) - Market turning with share at 52-week low

2025-11-05 11:14:00 Scandinavian ChemoTech (Q3 Review) - Strong momentum in revenue from treatment kits

2025-11-04 13:51:00 IRLAB Therapeutics (Q3 review) - Approaching study initiation

2025-11-04 13:50:00 Xbrane Biopharma (Q3 update) - Headwinds have continued

2025-11-03 11:40:00 Hansa Biopharma (Q3 Update) - Europe Below Expectations, but the US Will Drive Value

2025-11-03 10:39:00 Redeye Initiates Coverage of Boreo

2025-11-03 10:37:00 CTEK (Q3 Update) - Product launches in the spotlight

2025-11-03 10:36:00 Tradedoubler (Q3 Review) - Investing for Growth

2025-11-03 10:35:00 Modelon (Q3 Review) - Efficiency gains and expanding use cases

2025-10-31 11:44:00 SynAct (Q3 Update) - ADVANCE Approaching Full Recruitment

2025-10-30 14:52:00 OncoZenge (Q3 review) - Gearing up for a transformative 2026

2025-10-30 14:50:00 BioInvent (Q3 Update) - Phase II in NSCLC up and Running

2025-10-30 14:49:00 Senzime (Q3 Review) - In the right direction

2025-10-29 09:28:00 Truecaller (Q3 Review) - Soft quarter, strong foundation

2025-10-28 11:47:00 Annexin (Q3’25 Review) - Clinical study in focus

2025-10-28 11:46:00 Nitro Games (Q3 Review) - Balancing a soft market with new business optionality

2025-10-28 11:45:00 Heliospectra (Q3 Review) - Building the foundation for growth in 2026 and beyond

2025-10-27 14:32:00 Polygiene Group (Q3 Review) - Recovery in Sight

2025-10-27 14:31:00 Stille (Q3 update) - Prolonged headwind but valuation remains undemanding

2025-10-27 14:29:00 Xvivo Perfusion - And the beat goes on

2025-10-27 14:27:00 OXE Marine (Q3 Review) - Headwinds in Q3, but Promising Pipeline

2025-10-27 14:26:00 MedCap (Q3 review) - Healthy Q3 figures

2025-10-27 14:23:00 Sleep Cycle (Q3 Review) - Resilient profitability and diversification progress at trough valuation

2025-10-27 14:22:00 Lagercrantz (Q2 review) - Strong M&A pipeline

2025-10-27 14:21:00 SSH (Q3 Review) - Growth Authenticated

2025-10-27 14:20:00 Episurf Medical (Q3 review) - Growing the US customer base

2025-10-27 14:19:00 Sdiptech (Q3 Review) - Stable core becoming increasingly visible

2025-10-27 14:18:00 Momentum Group (Q3 Review) – No drama

2025-10-27 14:16:00 Sivers Semiconductors (Q3 Review) - Consistent Steps Toward a Stronger Business

2025-10-27 14:16:00 Safeture (Q3 Review) - The ARR Strikes Back

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Redeye

Prenumeration

Vem äger bolaget?

Redeye

Prenumeration

Vem äger bolaget?

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden